{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    45,
    49,
    137,
    53,
    56,
    59,
    60,
    62,
    63,
    64,
    65,
    66,
    69,
    73,
    74,
    76,
    77,
    90,
    110,
    111,
    112
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_2",
        "definition": "Day 1 of Cycle 1",
        "anchorType": "CycleStart",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Cycle 1 Day 1"
      },
      {
        "id": "anchor_1",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "informed consent"
      },
      {
        "id": "anchor_3",
        "definition": "procedure",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "procedure"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "once daily"
      },
      {
        "id": "rep_daily_7",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "OD"
      },
      {
        "id": "rep_daily_8",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "interval": "PT24H",
        "sourceText": "every 24 hours"
      },
      {
        "id": "rep_interval_3",
        "type": "Interval",
        "interval": "PT48H",
        "sourceText": "every 48 hours"
      },
      {
        "id": "rep_cycle_1",
        "type": "Cycle",
        "cycleLength": "P28D",
        "sourceText": "28-day cycle"
      },
      {
        "id": "rep_cycle_3",
        "type": "Cycle",
        "cycleLength": "P28D",
        "sourceText": "28 day cycle"
      },
      {
        "id": "rep_cycle_9",
        "type": "Cycle",
        "sourceText": "Cycle 1 Day 1"
      },
      {
        "id": "rep_cycle_12",
        "type": "Cycle",
        "sourceText": "C1D1"
      },
      {
        "id": "rep_cycle_15",
        "type": "Cycle",
        "exitCondition": "Disease progression",
        "sourceText": "until disease\nprogression"
      },
      {
        "id": "rep_cycle_17",
        "type": "Cycle",
        "exitCondition": "Disease progression",
        "sourceText": "until disease progression"
      },
      {
        "id": "rep_cycle_19",
        "type": "Cycle",
        "cycleLength": "P4D",
        "sourceText": "continue for 4 months"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "startOffset": "P1D",
        "endOffset": "P3D",
        "sourceText": "day 1 to 3"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "startOffset": "P1D",
        "endOffset": "P21D",
        "sourceText": "Days 1\nthrough 21"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "sourceText": "Screening Phase"
      },
      {
        "id": "rep_window_6",
        "type": "Continuous",
        "sourceText": "Treatment Phase"
      },
      {
        "id": "rep_window_7",
        "type": "Continuous",
        "sourceText": "Treatment \nPhase"
      },
      {
        "id": "rep_window_9",
        "type": "Continuous",
        "sourceText": "Follow-up Phase"
      },
      {
        "id": "rep_window_10",
        "type": "Continuous",
        "sourceText": "Follow-up\nPhase"
      },
      {
        "id": "rep_window_12",
        "type": "Continuous",
        "sourceText": "Follow-up \nPhase"
      },
      {
        "id": "rep_window_17",
        "type": "Continuous",
        "sourceText": "2 days before"
      },
      {
        "id": "rep_window_18",
        "type": "Continuous",
        "sourceText": "1 hour after"
      },
      {
        "id": "rep_window_19",
        "type": "Continuous",
        "sourceText": "42 days\nbefore"
      },
      {
        "id": "rep_window_20",
        "type": "Continuous",
        "sourceText": "21 days before"
      },
      {
        "id": "rep_window_21",
        "type": "Continuous",
        "sourceText": "72 hours\nafter"
      },
      {
        "id": "rep_window_22",
        "type": "Continuous",
        "sourceText": "2 hours post"
      },
      {
        "id": "rep_window_23",
        "type": "Continuous",
        "sourceText": "3 hours before"
      },
      {
        "id": "rep_llm_1",
        "type": "Cycle",
        "startOffset": "P0D",
        "interval": "P28D",
        "minObservations": 1,
        "exitCondition": "Disease progression or unacceptable toxicity",
        "sourceText": "repeat every 28 days"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "TREATMENT",
          "FOLLOW_UP",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "End of Treatment",
          "Screening",
          "Day 1",
          "End of Study",
          "Post-Treatment Follow-up",
          "Cycle 1 Day 1"
        ],
        "sourceText": "[{'condition': 'Subject experiences Grade 3 or higher infusion-related reaction', 'path': ['DOSE_INTERRUPTION', 'PERMANENT_DISCONTINUATION', 'EARLY_TERMINATION']}, {'condition': 'Subject experiences renal impairment or hematologic toxicity', 'path': ['DOSE_REDUCTION', 'DOSE_DELAY']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Sample",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 5; SINGLE signals: 1"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Window",
        "rationale": "WINDOW signals: 2; SINGLE signals: 1"
      },
      {
        "activityId": "Ecg",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Pe",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 3"
      },
      {
        "activityId": "Adverse Events",
        "executionType": "Single",
        "rationale": "EPISODE signals: 1; SINGLE signals: 2"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Single",
        "rationale": "SINGLE signals: 4"
      },
      {
        "activityId": "Laboratory Assessment",
        "executionType": "Window",
        "rationale": "WINDOW signals: 1; SINGLE signals: 1"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Single",
        "rationale": "SINGLE signals: 3"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Dosing",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Imaging",
        "executionType": "Single",
        "rationale": "SINGLE signals: 3"
      },
      {
        "activityId": "Biopsy",
        "executionType": "Single",
        "rationale": "SINGLE signals: 4"
      },
      {
        "activityId": "Epro",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1; RECURRING signals: 1"
      },
      {
        "activityId": "Screening Assessment",
        "executionType": "Single",
        "rationale": "The protocol indicates a screening phase to determine eligibility prior to randomization, which is a one-time assessment."
      },
      {
        "activityId": "Dose Administration",
        "executionType": "Single",
        "rationale": "The Time and Events Schedule for Dose Administration indicates repeated dosing of Daratumumab, Lenalidomide, and Dexamethasone across multiple study cycles."
      },
      {
        "activityId": "Safety Monitoring (Adverse Events)",
        "executionType": "Single",
        "rationale": "Safety monitoring and adverse event collection occur continuously from the time of informed consent through the end of the study treatment period."
      },
      {
        "activityId": "Dose Modification for Toxicity",
        "executionType": "Single",
        "rationale": "Adjustments to the study drug (e.g., Lenalidomide) are conditional workflows based on specific clinical decision points such as hematologic or non-hematologic toxicity levels."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "general",
        "text": "CR: complete response; FISH: fluorescence in situ hybridization; MRD: minimal residual disease; sCR: stringent complete response",
        "footnoteId": "fn_1",
        "structuredCondition": "definition_mapping",
        "appliesToActivityIds": [
          "CR",
          "FISH",
          "MRD",
          "sCR"
        ],
        "sourceText": "CR: complete response; FISH: fluorescence in situ hybridization; MRD: minimal residual disease; sCR:"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "general",
        "text": "* If one of these time points occurs within 1 month of suspected CR/sCR, a repeat bone marrow will not be requested. These bone marrow tests will only be required if patient's response is near CR or better by blood and urine evaluations.",
        "footnoteId": "fn_2",
        "structuredCondition": "if(timepoint.distance(suspected_CR_sCR) < P1M) { skip(bone_marrow_repeat) } else if(response_status >= near_CR) { require(bone_marrow) }",
        "appliesToActivityIds": [
          "Bone marrow test",
          "Repeat bone marrow"
        ],
        "sourceText": "* If one of these time points occurs within 1 month of suspected CR/sCR, a repeat bone marrow will n"
      },
      {
        "id": "fn_cond_3",
        "conditionType": "general",
        "text": "** Immunohistochemistry or immunofluorescence (both require kappa/lambda ratio from analysis of ≥100 plasma cells) or 2 to 4 color flow cytometry are acceptable methods to evaluate plasma cell clonality.",
        "footnoteId": "fn_3",
        "structuredCondition": "method_options(immunohistochemistry, immunofluorescence, flow_cytometry) AND requirement(plasma_cell_analysis >= 100)",
        "appliesToActivityIds": [
          "Plasma cell clonality evaluation",
          "Immunohistochemistry",
          "Immunofluorescence",
          "Flow cytometry"
        ],
        "sourceText": "** Immunohistochemistry or immunofluorescence (both require kappa/lambda ratio from analysis of ≥100"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Progression-Free Survival (PFS)",
        "endpointType": "Primary",
        "inputs": [
          "disease_progression_status",
          "date_of_confirmed_progression",
          "date_of_death",
          "date_of_randomization"
        ],
        "timeWindow": {
          "reference": "randomization",
          "duration": "until confirmed disease progression or death"
        },
        "algorithm": "PFS = (Date of first documented disease progression or death) - (Date of randomization)",
        "successCriteria": "Disease progression must be confirmed by the Sponsor prior to starting subsequent anti-myeloma therapy; primary analysis occurs at 390 PFS events.",
        "sourceText": "If disease progression has not occurred at the time of the End-of-Treatment visit, disease evaluations must continue until disease progression is confirmed. Subsequent anti-myeloma treatment will not "
      },
      {
        "id": "ep_2",
        "name": "Secondary: Overall Survival (OS)",
        "endpointType": "Secondary",
        "inputs": [
          "date_of_death",
          "date_of_randomization",
          "daratumumab_exposure_Arm_A"
        ],
        "timeWindow": {
          "reference": "randomization",
          "duration": "until death"
        },
        "algorithm": "OS = (Date of death) - (Date of randomization); Exploratory analysis may adjust for daratumumab exposure in Arm A (Rd) subjects.",
        "successCriteria": "Interim OS analysis occurs when approximately 260 deaths have occurred.",
        "sourceText": "Described that the second interim OS will now occur when approximately 260 deaths have occurred... Exploratory analysis may be performed to adjust for the effect daratumumab exposure may have on OS fo"
      },
      {
        "id": "ep_3",
        "name": "Secondary: Minimal Residual Disease (MRD) Negativity",
        "endpointType": "Secondary",
        "inputs": [
          "bone_marrow_aspirate",
          "CR_status",
          "sCR_status"
        ],
        "timeWindow": {
          "reference": "Cycle 1 Day 1 (C1D1)",
          "duration": "12, 18, 24, and 30 months post C1D1 (+/- 1 month)"
        },
        "algorithm": "MRD negativity assessed via bone marrow aspirate at time of suspected CR/sCR and specified intervals.",
        "successCriteria": "Achievement of MRD-negativity as defined by IMWG categories; tests only required if response is near CR or better.",
        "sourceText": "Samples are requested at time of suspected CR/sCR and at 12, 18, 24 and 30 months post C1D1 (+/-1 month)... These bone marrow tests will only be required if patient’s response is near CR or better by "
      },
      {
        "id": "ep_4",
        "name": "Secondary: Medical Resource Utilization (MRU)",
        "endpointType": "Secondary",
        "inputs": [
          "hospitalizations",
          "outpatient_visits",
          "emergency_room_visits"
        ],
        "timeWindow": {
          "reference": "study start",
          "duration": "throughout the study"
        },
        "algorithm": "Sum of primary non-protocol driven hospitalizations, outpatient visits, and emergency room visits.",
        "successCriteria": "Derived from data collected in the eCRF.",
        "sourceText": "Medical resource utilization (MRU) data, including primary non-protocol driven hospitalizations, outpatient visits, and emergency room visits, should be collected in the eCRF."
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Overall survival (OS)",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of randomization",
          "Date of death",
          "Date last known alive"
        ],
        "derivationRule": "date_of_death - date_of_randomization",
        "baselineDefinition": "Date of randomization",
        "analysisWindow": "From randomization until death or data cut-off",
        "imputationRule": "Censored at the date the subject was last known to be alive if death is not documented"
      },
      {
        "id": "dv_2",
        "name": "Time to next treatment",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of randomization",
          "Start date of next-line treatment"
        ],
        "derivationRule": "start_date_of_next_line_treatment - date_of_randomization",
        "baselineDefinition": "Date of randomization",
        "analysisWindow": "From randomization until start of next-line treatment",
        "imputationRule": "Not specified"
      },
      {
        "id": "dv_3",
        "name": "sCR rate",
        "variableType": "Categorical",
        "sourceVariables": [
          "Complete Response (CR) status",
          "Free light chain (FLC) ratio",
          "Bone marrow clonal cells"
        ],
        "derivationRule": "Percentage of subjects with CR AND normal FLC ratio AND absence of clonal cells in bone marrow",
        "baselineDefinition": "Post-baseline assessment",
        "analysisWindow": "During or after study treatment",
        "imputationRule": "Not specified"
      },
      {
        "id": "dv_4",
        "name": "Overall response rate (ORR)",
        "variableType": "Categorical",
        "sourceVariables": [
          "IMWG response criteria"
        ],
        "derivationRule": "Proportion of subjects achieving Partial Response (PR) or better",
        "baselineDefinition": "Post-baseline assessment",
        "analysisWindow": "During or after study treatment",
        "imputationRule": "Not specified"
      },
      {
        "id": "dv_5",
        "name": "Proportion of subjects who achieve VGPR or better",
        "variableType": "Categorical",
        "sourceVariables": [
          "IMWG response criteria"
        ],
        "derivationRule": "Proportion of subjects achieving Very Good Partial Response (VGPR), CR, or sCR",
        "baselineDefinition": "Post-baseline assessment",
        "analysisWindow": "During or after study treatment at the time of data cut-off",
        "imputationRule": "Not specified"
      },
      {
        "id": "dv_6",
        "name": "Time to response",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of randomization",
          "Date of first PR or better",
          "Date of progressive disease",
          "Date of last disease evaluation"
        ],
        "derivationRule": "date_of_first_PR_or_better - date_of_randomization",
        "baselineDefinition": "Date of randomization",
        "analysisWindow": "From randomization until first response",
        "imputationRule": "Censored at date of progressive disease or last disease evaluation before subsequent therapy"
      },
      {
        "id": "dv_7",
        "name": "Duration of response",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Date of initial documentation of response",
          "Date of first documented progressive disease",
          "Date of last disease evaluation"
        ],
        "derivationRule": "date_of_first_progressive_disease - date_of_initial_response",
        "baselineDefinition": "Date of initial documentation of PR or better",
        "analysisWindow": "From initial response until progression",
        "imputationRule": "Censored at last disease evaluation before subsequent anti-myeloma therapy"
      },
      {
        "id": "dv_8",
        "name": "QT interval corrected by Fridericia’s formula (QTcF)",
        "variableType": "Custom",
        "sourceVariables": [
          "QT interval",
          "RR interval"
        ],
        "derivationRule": "QT / (RR ^ (1/3))",
        "baselineDefinition": "Screening 12-lead ECG",
        "analysisWindow": "Screening",
        "imputationRule": "Not specified"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Treatment",
        "Follow Up",
        "End Of Study",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Treatment",
          "trigger": "Progress to Treatment"
        },
        {
          "fromState": "Treatment",
          "toState": "Follow Up",
          "trigger": "Progress to Follow Up"
        },
        {
          "fromState": "Follow Up",
          "toState": "End Of Study",
          "trigger": "Progress to End Of Study"
        },
        {
          "fromState": "Treatment",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Treatment": "TREATMENT",
        "Follow Up": "FOLLOW_UP",
        "End Of Study": "END_OF_STUDY",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "Dara-SC",
        "frequency": "QD",
        "route": "IV",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1800.0,
            "unit": "mg"
          },
          {
            "amount": 16.0,
            "unit": "mg"
          }
        ],
        "sourceText": "ensure continuity of study treatment, while limiting subjects’ time spent at the study center, subjects will be given the option to switch from daratumumab IV (16 mg/kg) to daratumumab subcutaneous (D"
      },
      {
        "id": "dosing_2",
        "treatmentName": "Dexamethasone",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 40.0,
            "unit": "mg"
          },
          {
            "amount": 20.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "75 years",
        "doseModifications": [
          "Dose reduction for elderly patients (e.g., >75 years) often reduced to 20mg"
        ],
        "sourceText": "d for dexamethasone “For 1 yr, 20 mg thereafter” is removed from dexamethasone to align figure with text. 6.1.3.1 Preinfusion Medication Text in the third bullet regarding dexamethasone is revised: De"
      },
      {
        "id": "dosing_llm_1",
        "treatmentName": "Daratumumab (IV)",
        "frequency": "Q2W",
        "route": "IV",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 16.0,
            "unit": "mg/kg",
            "description": "Standard IV dose"
          }
        ],
        "durationDescription": "Until disease progression or unacceptable toxicity",
        "doseModifications": [
          "Management of Infusion-related Reactions",
          "Infusion-Related Events of Grade 1 or Grade 2"
        ]
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Daratumumab (SC)",
        "frequency": "Q2W",
        "route": "SC",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1800.0,
            "unit": "mg",
            "description": "Fixed dose for subcutaneous administration"
          }
        ],
        "durationDescription": "Until disease progression or unacceptable toxicity",
        "doseModifications": [
          "Injection-site reaction management"
        ]
      },
      {
        "id": "dosing_llm_3",
        "treatmentName": "Lenalidomide",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 25.0,
            "unit": "mg",
            "description": "Standard starting dose"
          }
        ],
        "durationDescription": "28-day cycles until disease progression",
        "doseModifications": [
          "Dose reduction for renal impairment"
        ]
      }
    ],
    "visitWindows": [
      {
        "id": "visit_2",
        "visitName": "Screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "sourceText": "Screening Phase ........................................................................................................................ 91 9.1.3. Treatment Phase ....................................."
      },
      {
        "id": "visit_1",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "Dexamethasone (Arm A and Arm B)............................................................................................. 82 6.4. Dose Delays and Dose Modification.................................."
      },
      {
        "id": "visit_4",
        "visitName": "End of Study",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 3,
        "sourceText": "Final OS analysis Until End of Study.......................................................................................... 94 9.2. Efficacy........................................................."
      },
      {
        "id": "visit_5",
        "visitName": "EOT",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "Rationale: To clarify the mode of subject monitoring post end-of-treatment (EOT). Time and Events Schedule – Overview (Disease Evaluations)"
      },
      {
        "id": "visit_9",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "M-protein, provided baseline bone marrow plasma cell percentage was ≥30% Progressive disease (PD)† "
      },
      {
        "id": "visit_10",
        "visitName": "Visit 1",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "Forced Expiratory Volume in 1 second (FEV1) <50% of predicted normal. Note that FEV1 testing is required for subjects suspected of having COPD and subjects must be excluded if FEV1 <50% of predicted n"
      },
      {
        "id": "visit_llm_1",
        "visitName": "Screening Phase",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening Phase"
      },
      {
        "id": "visit_llm_3",
        "visitName": "Follow-up Phase",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 3,
        "epoch": "Follow-up Phase"
      },
      {
        "id": "visit_llm_4",
        "visitName": "Assessments Following the Positive Second Interim Analysis of PFS",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 4,
        "epoch": "Follow-up Phase"
      },
      {
        "id": "visit_llm_5",
        "visitName": "Assessments Following Implementation of Amendment 8",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 5,
        "epoch": "Follow-up Phase"
      },
      {
        "id": "visit_llm_6",
        "visitName": "Assessments Following the Interim OS Analysis",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 6,
        "epoch": "Follow-up Phase"
      },
      {
        "id": "visit_llm_7",
        "visitName": "Final CSR Analysis and Long-term Survival Follow-up",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 7,
        "epoch": "Follow-up Phase"
      },
      {
        "id": "visit_llm_8",
        "visitName": "Final OS analysis Until End of Study",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 8,
        "epoch": "Follow-up Phase"
      },
      {
        "id": "visit_6",
        "visitName": "randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 14,
        "epoch": "Treatment Phase",
        "sourceText": "subjects will be followed for survival, time from randomization to progression on the next line of therapy or death, whichever comes first (PFS2), second primary malignancies, and subsequent anti-myel"
      },
      {
        "id": "visit_8",
        "visitName": "Week 8",
        "targetDay": 50,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 15,
        "targetWeek": 8,
        "sourceText": "assessments that occur at Week 8 and Week 16 post-PD should be scheduled relative to the date of laboratory confirmed disease progression. 9.1.4. Follow-up"
      },
      {
        "id": "visit_3",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 16,
        "sourceText": "Follow-up Phase......................................................................................................................... 92 9.1.5. Assessments Following the Positive Second Interim Ana"
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1",
      "method": "",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_1",
          "name": "Age",
          "categories": [
            "<7 years",
            "≥7 years"
          ],
          "isBlocking": false,
          "sourceText": "international staging system (i vs ii vs iii\nsee attachment 8), region (north america vs other), and age (<75 vs ≥75) and then\nrandomized to treatment in a 1:1 ratio to either treatment arm a (rd alon"
        },
        {
          "id": "strat_2",
          "name": "Region",
          "categories": [
            "North America",
            "Europe",
            "Asia",
            "Rest of World"
          ],
          "isBlocking": false,
          "sourceText": "international staging system (i vs ii vs iii\nsee attachment 8), region (north america vs other), and age (<75 vs ≥75) and then\nrandomized to treatment in a 1:1 ratio to either treatment arm a (rd alon"
        },
        {
          "id": "strat_llm_1",
          "name": "International Staging System",
          "categories": [
            "I",
            "II",
            "III"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "JNJ-54767414  (daratumumab)\nClinical Protocol 54767414MMY3008 Amendment 9\nCONFIDENTIAL –FOIA Exemptions Apply in U.S. \n15\nApproved, Date: 20 July 2021\nThe overall reason for the amendment: The overall"
    }
  }
}